Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glecaprevir/Pibrentasvir for PTSD
NCT05446857Phase 3Completed
- Sponsor
- White River Junction VA Medical Center
- Start
- Apr 2023
- Primary completion
- Apr 2024
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of glecaprevir in post-traumatic stress disorder (PTSD), sponsored by White River Junction VA Medical Center. Started Apr 2023; status: completed.
02
Drugs
glecaprevir
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT05446857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05446857.